Patients with type 2 diabetes mellitus (T2DM), need optimum CV-Renal-Metabolic risk modification. Empagliflozin is the SGLT2-i agent with proven risk-reduction for MACE and CV Death, in patients with T2DM and CVD. Empagliflozin has also demonstrated improvement in several metabolic outcomes, like reduction in visceral adiposity, insulin resistance, and improvement in time in range. Stabilization of kidney function has been a clinically relevant outcome for patients with T2DM. 1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 8 th February 2021 from 06:00 PM IST onwards.
In this webinar, the expert panel (Dr. Melanie Davies, and Dr. V. Mohan) will share their opinion on the role of SGLT2-inhibitors in cardio-renal metabolic risk management in T2DM. We invite you to share your questions which will be answered by the…
